Restricted accessResearch articleFirst published online 2017-06
Bone Marrow-Derived Mesenchymal Stem Cells Attenuate Immune-Mediated Liver Injury and Compromise Virus Control During Acute Hepatitis B Virus Infection in Mice
Mesenchymal stem cells (MSCs) have been used as therapeutic tools not only for their ability to differentiate toward different cells, but also for their unique immunomodulatory properties. However, it is still unknown how MSCs may affect immunity during hepatitis B virus (HBV) infection. This study was designed to explore the effect of bone marrow-derived MSCs (BM-MSCs) on hepatic natural killer (NK) cells in a mouse model of acute HBV infection. Mice were injected with 1 × 106 BM-MSCs, which stained with chloromethyl derivatives of fluorescein diacetate fluorescent probe, 24 h before hydrodynamic injection of viral DNA (pHBV1.3) through the tail vein. In vivo imaging system revealed that BM-MSCs were accumulated in the injured liver, and they attenuated immune-mediated liver injury during HBV infection, as shown by lower alanine aminotransferase levels, reduced proinflammatory cytokine production, and decreased inflammatory cell infiltration in the liver. Importantly, administration of BM-MSCs restrained the increased expression of natural-killer group 2, member D (NKG2D), an important receptor required for NK cell activation in the liver from HBV-infected mice. BM-MSCs also reduced NKG2D expression on NK cells and suppressed the cytotoxicity of NK cells in vitro. Furthermore, BM-MSC-derived transforming growth factor-β1 suppressed NKG2D expression on NK cells. As a consequence, BM-MSC treatment enhanced HBV gene expression and replication in vivo. These results demonstrate that adoptive transfer of BM-MSCs influences innate immunity and limits immune-mediated liver injury during acute HBV infection by suppressing NK cell activity. Meanwhile, the effect of BM-MSCs on prolonging virus clearance needs to be considered in the future.
Get full access to this article
View all access options for this article.
References
1.
TrepoC, ChanHL and LokA. (2014). Hepatitis B virus infection. Lancet, 384:2053–2063.
2.
GaoB, JeongWI and TianZ. (2008). Liver: an organ with predominant innate immunity. Hepatology, 47:729–736.
3.
BertolettiA and FerrariC. (2016). Adaptive immunity in HBV infection. J Hepatol, 64:S71–S83.
4.
MainiMK and GehringAJ. (2016). The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol, 64:S60–S70.
5.
HanQ, ZhangC, ZhangJ and TianZ. (2013). The role of innate immunity in HBV infection. Semin Immunopathol, 35:23–38.
6.
SunC, FuB, GaoY, LiaoX, SunR, TianZ and WeiH. (2012). TGF-beta1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog, 8:e1002594.
7.
TianZ, ChenY and GaoB. (2013). Natural killer cells in liver disease. Hepatology, 57:1654–1662.
8.
Di NicolaM, Carlo-StellaC, MagniM, MilanesiM, LongoniPD, MatteucciP, GrisantiS and GianniAM. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood, 99:3838–3843.
9.
RosadoMM, BernardoME, ScarsellaM, ConfortiA, GiordaE, BiaginiS, CascioliS, RossiF, GuzzoI, VivarelliM, Dello StrologoL, EmmaF, LocatelliF and CarsettiR. (2015). Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev, 24:93–103.
10.
SpaggiariGM, CapobiancoA, AbdelrazikH, BecchettiF, MingariMC and MorettaL. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood, 111:1327–1333.
11.
DjouadF, CharbonnierLM, BouffiC, Louis-PlenceP, BonyC, ApparaillyF, CantosC, JorgensenC and NoelD. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells, 25:2025–2032.
12.
JiangXX, ZhangY, LiuB, ZhangSX, WuY, YuXD and MaoN. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood, 105:4120–4126.
13.
TjwaET, van OordGW, HegmansJP, JanssenHL and WoltmanAM. (2011). Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol, 54:209–218.
MorettaL and MorettaA. (2004). Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J, 23:255–259.
16.
BottinoC, CastriconiR, MorettaL and MorettaA. (2005). Cellular ligands of activating NK receptors. Trends Immunol, 26:221–226.
17.
NielsenN, PascalV, FasthAE, SundstromY, GalsgaardED, AhernD, AndersenM, BaslundB, BartelsEM, BliddalH, FeldmannM, MalmstromV, BergL, SpeeP and SoderstromK. (2014). Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblasts. Immunology, 142:581–593.
18.
SeneD, LevasseurF, AbelM, LambertM, CamousX, HernandezC, PeneV, RosenbergAR, Jouvin-MarcheE, MarchePN, CacoubP and Caillat-ZucmanS. (2010). Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog, 6:e1001184.
19.
SakaidaI, TeraiS, YamamotoN, AoyamaK, IshikawaT, NishinaH and OkitaK. (2004). Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology, 40:1304–1311.
20.
AliG and MasoudMS. (2012). Bone marrow cells ameliorate liver fibrosis and express albumin after transplantation in CCl(4)-induced fibrotic liver. Saudi J Gastroenterol, 18:263–267.
21.
AlAhmariLS, AlShenaifiJY, AlAnaziRA and AbdoAA. (2015). Autologous bone marrow-derived cells in the treatment of liver disease patients. Saudi J Gastroenterol, 21:5–10.
22.
HudspethK, PontariniE, TentorioP, CiminoM, DonadonM, TorzilliG, LugliE, Della BellaS, GershwinME and MavilioD. (2013). The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun, 46:55–65.
23.
OlivieroB, VarchettaS, PaudiceE, MicheloneG, ZaramellaM, MavilioD, De FilippiF, BrunoS and MondelliMU. (2009). Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology, 137:1151–1160, 1160.e1–1160.e7.
24.
ZhangZ, ZhangS, ZouZ, ShiJ, ZhaoJ, FanR, QinE, LiB, LiZ, XuX, FuJ, ZhangJ, GaoB, TianZ and WangFS. (2011). Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology, 53:73–85.
25.
VivierE, RauletDH, MorettaA, CaligiuriMA, ZitvogelL, LanierLL, YokoyamaWM and UgoliniS. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331:44–49.
26.
LiF, WeiH, WeiH, GaoY, XuL, YinW, SunR and TianZ. (2013). Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology, 144:392–401.
27.
HuangLR, WuHL, ChenPJ and ChenDS. (2006). An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A, 103:17862–17867.
28.
HouX, ZhouR, WeiH, SunR and TianZ. (2009). NKG2D-retinoic acid early inducible-1 recognition between natural killer cells and Kupffer cells in a novel murine natural killer cell-dependent fulminant hepatitis. Hepatology, 49:940–949.
29.
ZouY, ChenT, HanM, WangH, YanW, SongG, WuZ, WangX, ZhuC, LuoX and NingQ. (2010). Increased killing of liver NK cells by Fas/Fas ligand and NKG2D/NKG2D ligand contributes to hepatocyte necrosis in virus-induced liver failure. J Immunol, 184:466–475.
30.
PittengerMF, MackayAM, BeckSC, JaiswalRK, DouglasR, MoscaJD, MoormanMA, SimonettiDW, CraigS and MarshakDR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284:143–147.
31.
JiangY, JahagirdarBN, ReinhardtRL, SchwartzRE, KeeneCD, Ortiz-GonzalezXR, ReyesM, LenvikT, LundT, BlackstadM, DuJ, AldrichS, LisbergA, LowWC, LargaespadaDA and VerfaillieCM. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418:41–49.
32.
UccelliA, PistoiaV and MorettaL. (2007). Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol, 28:219–226.
33.
ShiY, HuG, SuJ, LiW, ChenQ, ShouP, XuC, ChenX, HuangY, ZhuZ, HuangX, HanX, XieN and RenG. (2010). Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res, 20:510–518.
34.
DazziF, LopesL and WengL. (2012). Mesenchymal stromal cells: a key player in ‘innate tolerance’?. Immunology, 137:206–213.
35.
RenG, ZhangL, ZhaoX, XuG, ZhangY, RobertsAI, ZhaoRC and ShiY. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2:141–150.
36.
ShengH, WangY, JinY, ZhangQ, ZhangY, WangL, ShenB, YinS, LiuW, CuiL and LiN. (2008). A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res, 18:846–857.
37.
KramperaM, GlennieS, DysonJ, ScottD, LaylorR, SimpsonE and DazziF. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood, 101:3722–3729.
38.
SatoK, OzakiK, OhI, MeguroA, HatanakaK, NagaiT, MuroiK and OzawaK. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood, 109:228–234.
39.
LiuWH, LiuJJ, WuJ, ZhangLL, LiuF, YinL, ZhangMM and YuB. (2013). Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway. PLoS One, 8:e55487.
40.
SpaggiariGM, CapobiancoA, BecchettiS, MingariMC and MorettaL. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107:1484–1490.
41.
LiC, KongY, WangH, WangS, YuH, LiuX, YangL, JiangX, LiL and LiL. (2009). Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol, 50:1174–1183.
42.
JiJF, HeBP, DheenST and TaySS. (2004). Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells, 22:415–427.
43.
BarbashIM, ChouraquiP, BaronJ, FeinbergMS, EtzionS, TessoneA, MillerL, GuettaE, ZiporiD, KedesLH, KlonerRA and LeorJ. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation, 108:863–868.
44.
StrossL, GuntherJ, GasteigerG, AsenT, GrafS, AichlerM, EspositoI, BuschDH, KnolleP, SparwasserT and ProtzerU. (2012). Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology, 56:873–883.
45.
PeppaD, MiccoL, JavaidA, KennedyPT, SchurichA, DunnC, PallantC, EllisG, KhannaP, DusheikoG, GilsonRJ and MainiMK. (2010). Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog, 6:e1001227.
46.
LiangG, LiuG, KitamuraK, WangZ, ChowdhuryS, MonjurulAM, WakaeK, KouraM, ShimaduM, KinoshitaK and MuramatsuM. (2015). TGF-beta suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex. PLoS Pathog, 11:e1004780.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
